Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Regional Scope
1.1.2 Market Definitions
1.1.3 Estimates and Forecast Timeline
1.2 Objectives
1.2.1 Objective – 1
1.2.2 Objective – 2
1.2.3 Objective – 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 GVR’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country wise market estimation using bottom-up approach
1.8 List of Secondary Sources
1.9 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Product and Type Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Peptide Drug Conjugates Market Variables, Trends, and Scope
3.1 Peptide Drug Conjugates Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Cancer Prevalence and Related Mortality
3.2.1.1.1 Cancer Incidence Data
3.2.1.2 Robust Clinical Trial Pipeline
3.2.2 Market Restraint Analysis
3.2.2.1 Long R&D Time and Slow Clinical Development Process
3.3 Peptide Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTLE Analysis
3.4 Pipeline Analysis
Chapter 4 Peptide Drug Conjugates Market – Segment Analysis, by Type, 2018 – 2030 (USD Million)
4.1 Peptide Drug Conjugates Market: Type Movement Analysis
4.2 Peptide Drug Conjugates Market Estimates & Forecast, By Type (USD Million)
4.2.1 Therapeutics
4.2.2 Diagnostics
Chapter 5 Peptide Drug Conjugates Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Peptide Drug Conjugates Market: Product Movement Analysis
5.2 Peptide Drug Conjugates Market Estimates & Forecast, By Product (USD Million)
5.2.1 OctreoScan
5.2.2 Lutathera
5.2.3 Pepaxto/ Melflufen
5.2.4 ANG1005
5.2.5 BT1718
Chapter 6 Peptide Drug Conjugates Market: Regional Estimates and Trend Analysis by Product and Type, 2018 – 2030 (USD Million)
6.1 Peptide Drug Conjugates Market: Regional Outlook
6.2 North America
6.2.1 North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.2.4 Competitive/Market Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.3.4 Competitive/Market Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 Target Disease Prevalence
6.3.2.3 UK Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2.4 Competitive/Market Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Target Disease Prevalence
6.3.3.3 Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.3.4 Competitive/Market Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 Target Disease Prevalence
6.3.4.3 France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.4.4 Competitive/Market Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Spain
6.3.5.1 Key Country Dynamics
6.3.5.2 Target Disease Prevalence
6.3.5.3 Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.5.4 Competitive/Market Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Italy
6.3.6.1 Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.6.2 Competitive/Market Scenario
6.3.6.3 Regulatory Framework
6.3.6.4 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Target Disease Prevalence
6.3.7.3 Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.7.4 Competitive/Market Scenario
6.3.7.5 Regulatory Framework
6.3.7.2 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Target Disease Prevalence
6.3.8.3 Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.8.4 Competitive/Market Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Target Disease Prevalence
6.3.9.3 Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.9.4 Competitive/Market Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Target Disease Prevalence
6.4.2.3 Japan Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2.4 Competitive/Market Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 Target Disease Prevalence
6.4.3.3 China Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.3.4 Competitive/Market Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 Target Disease Prevalence
6.4.4.3 India Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.4.4 Competitive/Market Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Target Disease Prevalence
6.4.5.3 Australia Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.5.4 Competitive/Market Scenario
6.4.5.5 Regulatory Framework
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.6.3 Competitive/Market Scenario
6.4.6.4 Regulatory Framework
6.4.6.5 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.7.3 Competitive/Market Scenario
6.4.7.4 Regulatory Framework
6.4.7.5 Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Target Disease Prevalence
6.5.2.3 Brazil Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2.4 Competitive/Market Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Target Disease Prevalence
6.5.3.3 Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.3.4 Competitive/Market Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Target Disease Prevalence
6.5.4.3 Argentina Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.4.4 Competitive/Market Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6 MEA
6.6.1 MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 Target Disease Prevalence
6.6.2.3 South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2.4 Competitive/Market Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Target Disease Prevalence
6.6.3.3 Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.3.4 Competitive/Market Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 Target Disease Prevalence
6.6.4.3 UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.4.4 Competitive/Market Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Target Disease Prevalence
6.6.5.3 Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.5.4 Competitive/Market Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Mapping
7.1.1 New Launches
7.1.2 Collaboration
7.1.3 Partnership
7.1.4 Others
7.2 Company Profiles
7.2.1 Novartis AG.
7.2.1.1 Company Overview
7.2.1.2 Financial Performance
7.2.1.3 Product Benchmarking
7.2.1.4 Strategic Initiatives
7.2.2 Bicycle Therapeutics
7.2.2.1 Company Overview
7.2.2.2 Financial Performance
7.2.2.3 Product Benchmarking
7.2.2.4 Strategic Initiatives
7.2.3 AstraZeneca
7.2.3.1 Company Overview
7.2.3.2 Financial Performance
7.2.3.3 Product Benchmarking
7.2.3.4 Strategic Initiatives
7.2.4 Cybrexa Therapeutics
7.2.4.1 Company Overview
7.2.4.2 Financial Performance
7.2.4.3 Product Benchmarking
7.2.4.4 Strategic Initiatives
7.2.5 Oncopeptides Inc.
7.2.5.1 Company Overview
7.2.5.2 Financial Performance
7.2.5.3 Product Benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 Angiochem Inc.
7.2.6.1 Company Overview
7.2.6.2 Financial Performance
7.2.6.3 Product Benchmarking
7.2.7 Innovasium Soricimed Biopharma
7.2.7.1 Company Overview
7.2.7.2 Financial performance
7.2.7.3 Product Benchmarking
7.2.7.4 Strategic Initiatives
7.2.8 Theratechnologies
7.2.8.1 Company Overview
7.2.8.2 Financial performance
7.2.8.3 Product Benchmarking
7.2.8.4 Strategic Initiatives
Chapter 8 Conclusion